4.22

1.44% 0.06

After Hours: 4.22

Foghorn Therapeutics Inc (FHTX)

Overview News Price History Option Chain Financials Why FHTX Down? Discussions Forecast

Foghorn Therapeutics Inc stock is traded at $4.22, with a volume of 164.70K. It is up +1.44% in the last 24 hours and down -21.71% over the past month. Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Previous Close:

$4.16

Open:

$4.15

24h Volume:

164.70K

Relative Volume:

1.07

Market Cap:

$247.77M

Revenue:

$30.91M

Net Income/Loss:

$-74.28M

P/E Ratio:

-3.4638

EPS:

-1.2183

Net Cash Flow:

$-86.15M

1W Performance:

+11.35%

1M Performance:

-21.71%

6M Performance:

-8.66%

1Y Performance:

+1.93%

1-Day Range:

$4.05

$4.33

1-Week Range:

$3.59

$4.33

52-Week Range:

$3.27

$6.95

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name

Foghorn Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

617-586-3100

Address

500 TECHNOLOGY SQUARE, CAMBRIDGE

Employee

106

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

FHTX's Discussions on Twitter

Compare FHTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FHTX Foghorn Therapeutics Inc	4.22	244.25M	30.91M	-74.28M	-86.15M	-1.2183
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Resumed	Jefferies	Buy
Dec-18-25	Initiated	BTIG Research	Buy
Nov-07-25	Initiated	Guggenheim	Buy
Sep-17-25	Resumed	B. Riley Securities	Buy
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform
Jan-30-25	Initiated	B. Riley Securities	Buy
Sep-03-24	Initiated	Jefferies	Buy
Aug-19-24	Initiated	Evercore ISI	Outperform
Mar-28-23	Initiated	BofA Securities	Buy
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Nov-22-21	Initiated	H.C. Wainwright	Buy
Nov-17-20	Initiated	Cowen	Outperform
Nov-17-20	Initiated	Goldman	Buy
Nov-17-20	Initiated	Morgan Stanley	Overweight
Nov-17-20	Initiated	Wedbush	Outperform

View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

May 21, 2026

Foghorn Therapeutics (FHTX) Posts Record Q1 2026 — EPS $-0.29 Blows Past EstimatesLive Trade Sharing - Newser

May 21, 2026

May 18, 2026

Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN

May 18, 2026

May 16, 2026

FHTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

May 16, 2026

May 15, 2026

BVF entities disclose shares, 6.05M pre‑funded warrants in Foghorn (FHTX) - Stock Titan

May 15, 2026

EDGAR Filing Documents for 0001628280-25-014475 - SEC.gov

May 15, 2026

May 14, 2026

[SCHEDULE 13G/A] Foghorn Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan

May 14, 2026

May 13, 2026

Foghorn Therapeutics discloses new EP300 degradation inducers - BioWorld News

May 13, 2026

May 12, 2026

Foghorn Therapeutics schedules trio of investor events to spotlight oncology developments - Traders Union

May 12, 2026

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Investing News Network

May 12, 2026

May 11, 2026